(Q36898681)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17667958%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

The pipeline and future of drug development in schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17667958%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17667958%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

B L Roth

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17667958%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

English

0 references

publication date

31 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17667958%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17667958%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17667958%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17667958%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

904-922

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17667958%20AND%20SRC:MED&resulttype=core&format=json

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

Quality of life as a predictor for change in disability in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

Schizophrenia: a subcortical neurotransmitter imbalance syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

Initiation and adaptation: a paradigm for understanding psychotropic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Why academic drug discovery makes sense

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Finding new tricks for old drugs: an efficient route for public-sector drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Medicine. What are the right targets for psychopharmacology?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

How can drug discovery for psychiatric disorders be improved?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Cognition in schizophrenia: impairments, determinants, and functional importance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine receptors in human and calf brains, using [3H]apomorphine and an antipsychotic drug

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Target-based drug discovery: is something wrong?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Modulation of memory fields by dopamine D1 receptors in prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine D3 receptor antagonists as therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine D3 receptor ligands with antagonist properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine D4 receptors: beyond schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine D4 receptor-deficient mice display cortical hyperexcitability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

3-Methoxytyramine Is the Major Metabolite of Released Dopamine in the Rat Frontal Cortex: Reassessment of the Effects of Antipsychotics on the Dynamics of Dopamine Release and Metabolism in the Frontal Cortex, Nucleus Accumbens, and Striatum by a Sim

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Cognitive improvement during Tolcapone treatment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

5-HT2C receptor activation decreases appetite and body weight in obese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Drugs and valvular heart disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

5-HT6 receptors: a novel target for cognitive enhancement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Involvement of 5-HT6 receptors in nigro-striatal function in rodents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Guanfacine treatment of cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Cognitive functions of cortical acetylcholine: toward a unifying hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Towards a muscarinic hypothesis of schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Muscarinic receptors as a target for drugs treating schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Progress toward a high-affinity allosteric enhancer at muscarinic M1 receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Nicotine use in schizophrenia: the self medication hypotheses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Nicotinic agonists and psychosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Discovery and SAR of org 24598-a selective glycine uptake inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Antipsychotic-like effect of the AMPA receptor antagonist LY326325 as indicated by suppression of conditioned avoidance response in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

The environment and schizophrenia: the role of cannabis use.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: lithium treatment normalizes tachykinins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Neurotensin: role in psychiatric and neurological diseases.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Secretin for refractory schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Neurosteroids ameliorate conditioned fear stress: an association with sigma receptors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

A pathophysiological paradigm for the therapy of psychiatric disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Genomics and the Human Genome Project: implications for psychiatry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Schizophrenia: neural mechanisms for novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Cure therapeutics and strategic prevention: raising the bar for mental health research

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

Neurobiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

The neurodevelopmental model of schizophrenia: update 2005.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002062

7 January 2021